Home › Sickle Cell Disease › NCT05799118

Study of the Role of Genetic Modifiers in Hemoglobinopathies

Who can join

Ages 2 and older · All sexes

Inclusion Criteria:

* Clinical diagnosis of an inherited hemoglobinopathy, including sickle cell disease (SCD), β-thalassemia, and α-thalassemia; all genotypes will be considered.
* Age ≥ 2 years old at the time of the collection of the phenotypic data.
* There will be no limits on study participants in terms of gender, ethnicity, morbidities.

Exclusion Criteria:

* Patients treated with stem cell transplantation or genetic therapy.
* Age \< 2 years old at the time of the collection of the phenotypic data.
* Patient or legal representative for minors unwilling or unable to give consent.

About the study

This study will investigate the role of genetic modifiers in hemoglobinopathies through a large-scale, multi-ethnic genome-wide association study (GWAS).

What is being tested

• GWAS (genetic)

Sponsor: Cyprus Institute of Neurology and Genetics · Participants: 30,000 · Started: Oct 1, 2022

Contact the study team

• Petros Kountouris, PhD · Phone: 22392623

Official record on ClinicalTrials.gov — NCT05799118

Locations in the U.S.

Conditions

• Sickle Cell Disease
• beta-Thalassemia
• Hemoglobinopathies
• Thalassemia

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.